Summary of findings 2. Rituximab versus placebo.
| Rituximab versus placebo | ||||||
| Patient or population: patients with active ulcerative colitis Settings: Outpatient Intervention: Rituximab versus placebo | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Control | Rituximabversus placebo | |||||
| IBDQ at week 12 | The mean IBDQ change score in the placebo group was 2 | The mean IBDQ score in the intervention group was 15 points higher | 22 (1 study) | ⊕⊝⊝⊝ very low1, 2 | ||
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Downgraded two levels due to small sample size (24 participants)
2 Downgraded one level due to high risk of bias